Clinical Trial: A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.

U.S., June 25 -- ClinicalTrials.gov registry received information related to the study (NCT07666555) titled 'A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.' on June 14.

Brief Summary: To evaluate the efficacy and safety of Culmerciclib combined with fulvestrant compared with investigator-selected CDK4/6 inhibitors combined with fulvestrant in patients with HR-positive/HER2-negative breast cancer who have progressed after first-line endocrine therapy

Study Start Date: June 06

Study Type: INTERVENTIONAL

Condition: Breast Cancer

Intervention: DRUG: CDK4/6 inhibitor

investigator's choice of CDK4/6 inhib...